Skip to Main Content

Guanfacine to Improve Substance Use Outcomes in Women

Conditions

Addictive Behaviors | Mental Health & Behavioral Research

Phase II

What is the purpose of this trial?

Detailed Description:

This study proposes to extend previous Phase I experimental work to address the following specific aims: (1) assess GUA's target engagement of drug craving and cognitive flexibility in a laboratory challenge session and in a 10-week outpatient clinical study, (2) demonstrate target validation by showing that reduced drug craving and improved cognitive flexibility will predict lower drug use outcomes during the 10-week clinical trial in SUD women, and finally, (3) evaluate data replication and scalability of GUA target effects across two clinical sites (Yale and SUNY-Stony Brook).

  • Trial with
    National Institute on Drug Abuse (NIDA)
  • Start Date
    09/16/2019
  • End Date
    06/29/2021
Trial Image

For more information about this study, contact:

Rachel Hart

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/25/2019
  • Study HIC
    #2000025416